Revenue
2020
2021
2022
2023
2024
2025
Ensysce Biosciences, Inc. (ENSC)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M | $3.9M | — | — |
| Research & development | $10.4M | $7.2M | $7.6M | $19.8M | $4.7M | $4.4M | — | — |
| Operating expenses | $15.3M | $11.9M | $12.9M | $26.7M | $23.4M | $5.5M | $3.3M | $1.6M |
| Operating income | −$10.2M | −$6.7M | −$10.7M | −$24.2M | −$19.9M | −$1.6M | −$3.3M | −$959,240 |
| Net income | −$10.2M | −$8.0M | −$10.6M | −$24.2M | −$29.1M | $4.3M | −$1.1M | $2.1M |
| Basic EPSper diluted share | -$3.98 | -$11.45 | -$70.40 | -$139.42 | -$29.64 | $0.00 | -$0.63 | -$0.21 |
| Diluted EPSper diluted share | -$3.98 | -$11.45 | -$70.40 | -$139.42 | -$1.48 | $0.00 | -$0.63 | -$0.21 |